Breast Biopsy - Market Insights, Competitive Landscape, and Market Forecast - 2034

Breast Biopsy Market Summary

Overview:

• The Breast Biopsy market is estimated at USD 2.47 billion in 2025 and is projected to reach USD 4.12 billion by 2034. Growth is anchored in the rising global burden of breast cancer, the rapid expansion of mammography and supplemental screening programs, and the increasing clinical shift toward minimally invasive, image-guided biopsy over open surgical biopsy.
• The global Breast Biopsy market is growing at a CAGR of 5.8% during the forecast period from 2026 to 2034.
• By product type, the biopsy systems segment dominated the Breast Biopsy market with a 34% share in 2025.
• By application, the core needle biopsy segment dominated the Breast Biopsy market with a 46% share in 2025.
• By guidance technology, the ultrasound guidance segment dominated the Breast Biopsy market with a 42% share in 2025.
• By lesion type, the non-palpable lesion segment dominated the Breast Biopsy market with a 64% share in 2025.
• By end-user, the hospitals segment dominated the Breast Biopsy market with a 45% share in 2025.
• North America dominated the global Breast Biopsy market revenue with a 41% share in 2025, representing the highest regional market share globally.

A breast biopsy is a minimally invasive or surgical diagnostic procedure that removes a tissue or fluid sample from a suspicious breast lesion identified on mammography, ultrasound, magnetic resonance imaging (MRI), or clinical examination, so that the sample can be evaluated histologically or cytologically for malignancy. Because early and accurate tissue diagnosis is central to breast cancer management, breast biopsy has become the diagnostic gold standard following an abnormal screening or diagnostic finding, largely displacing open surgical excision for initial diagnosis. The market is organized by product type across biopsy needles, biopsy systems, guidance systems, and accessories; by application spanning core needle biopsy, fine needle aspiration, vacuum-assisted biopsy, and surgical biopsy; by guidance technology across ultrasound, stereotactic, MRI, tomosynthesis/mammography, and other modalities; by lesion type across palpable and non-palpable lesions; and by end-user, led by hospitals. Driven by rising breast cancer incidence, expanding organized and opportunistic screening programs, growing dense-breast awareness, and continuous innovation in vacuum-assisted and image-guided biopsy platforms, the breast biopsy market has become a foundational pillar of the global breast-care diagnostic pathway.

Breast Biopsy Market Key Growth Drivers

• The rising global burden of breast cancer is expanding demand for timely tissue diagnosis, with breast cancer remaining the most commonly diagnosed cancer among women worldwide and incidence continuing to climb across both developed and emerging markets.
• The rapid expansion of organized mammography screening, digital breast tomosynthesis, and supplemental ultrasound and MRI screening programs is increasing the detection of small, often non-palpable lesions that require image-guided biopsy for confirmation.
• Growing dense-breast awareness and notification requirements are driving adoption of supplemental screening technologies such as automated breast ultrasound (ABUS), which in turn is feeding a larger pipeline of biopsy referrals.
• A structural shift from open surgical biopsy toward minimally invasive core needle and vacuum-assisted biopsy is reducing procedural cost, scarring, and recovery time while improving diagnostic accuracy and patient throughput.
• Continuous product innovation, including MRI-compatible vacuum-assisted systems, contrast-enhanced mammography-guided biopsy, and AI-assisted targeting, is improving sampling accuracy and expanding the addressable procedure base.
• Expanding outpatient and ambulatory surgical center capacity, supported by favorable reimbursement in developed markets, is increasing patient access to same-day, image-guided breast biopsy procedures.
• Government and non-profit early-detection initiatives across emerging economies are broadening breast cancer awareness and screening infrastructure, gradually increasing biopsy volumes outside North America and Europe.

Key Companies in Breast Biopsy Market

The competitive landscape is led by the following active manufacturers:

• Hologic, Inc.
• BD (Becton, Dickinson and Company)
• Mammotome
• Argon Medical Devices
• Merit Medical Systems, Inc.
• GE HealthCare
• Cook Medical
• Stryker
• Planmed Oy
• Siemens Healthineers

Factors Contributing to the Growth of the Breast Biopsy Market

Market Drivers

Rising Global Breast Cancer Incidence

The most powerful driver of the Breast Biopsy market is the persistently rising global incidence of breast cancer, which remains the most frequently diagnosed cancer among women across both high-income and low- and middle-income countries. As screening coverage widens and life expectancy rises, the absolute number of women requiring diagnostic work-up for a suspicious breast finding continues to grow. Because tissue confirmation through biopsy is required before any treatment pathway, whether benign monitoring, surgery, or systemic therapy, every additional suspicious finding translates directly into biopsy volume. This dynamic anchors durable, recurring demand for biopsy needles, vacuum-assisted systems, and guidance platforms across the forecast period.

Expansion of Mammography and Supplemental Screening

The continued expansion of organized mammography screening, together with growing adoption of digital breast tomosynthesis and supplemental ultrasound and MRI screening for women with dense breast tissue, is driving detection of smaller and increasingly non-palpable lesions. Because these lesions cannot be reliably sampled by palpation alone, they require stereotactic, ultrasound, tomosynthesis, or MRI-guided biopsy, directly expanding the addressable procedure base for image-guided breast biopsy systems. Dense-breast notification laws in the United States and similar initiatives elsewhere are reinforcing adoption of automated breast ultrasound and other supplemental modalities, further growing the referral pipeline into biopsy.

Market Restraints

Despite strong underlying demand, the Breast Biopsy market faces material constraints. Recurring supply disruptions for stereotactic biopsy needles, including a nationwide U.S. shortage that prompted FDA action and manufacturer field safety notices in 2025 and 2026, have periodically constrained procedure capacity and highlighted the fragility of single-source component supply chains. The relatively high upfront cost of vacuum-assisted, MRI-compatible, and tomosynthesis-guided biopsy systems can limit adoption among smaller clinics and in price-sensitive emerging markets, while reimbursement for advanced image-guided procedures remains uneven outside North America and parts of Europe. Procedural risks, including bleeding, inadequate or non-diagnostic sampling, and the need for repeat biopsy, continue to affect a minority of cases and require ongoing physician training. A shortage of trained radiologists and breast imaging technologists in several regions constrains the pace at which additional biopsy capacity can be brought online, and regulatory clearance timelines for new devices can delay the commercial rollout of innovation. Together, these capital, supply-chain, workforce, and regulatory factors moderate the pace of growth even as the underlying drivers of rising incidence, screening expansion, and technological advancement remain firmly intact.

Breast Biopsy Market Segment Analysis

The Breast Biopsy Market by product type (biopsy needles, biopsy systems, guidance systems, accessories), biopsy technique (core needle biopsy, fine needle aspiration, vacuum-assisted biopsy, surgical biopsy), guidance technology (ultrasound, stereotactic, mri, tomosynthesis/mammography, others), lesion type (palpable and non-palpable), end-users (hospitals, diagnostic imaging centers, specialty clinics, ambulatory surgical centers, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Biopsy Systems.

The biopsy systems segment accounted for 34% of the Breast Biopsy market in 2025. Biopsy systems, including vacuum-assisted and automated core biopsy platforms, are the leading product type because they represent the highest-value capital and consumable-driver equipment purchased by hospitals and imaging centers, combining reusable driver units with recurring probe and consumable revenue. Their ability to retrieve larger, more consistent tissue samples in a single insertion has made them the preferred technology for both diagnostic and therapeutic excision of breast lesions, particularly for non-palpable, calcification-associated, and MRI-detected findings. Guidance systems form a closely related and fast-growing category as facilities upgrade stereotactic and tomosynthesis-guided platforms, while biopsy needles remain the highest-volume, lowest-cost product used across core needle and fine needle procedures. Accessories, including tissue markers and localization devices, are growing quickly as post-biopsy site marking becomes standard practice ahead of potential surgery. Nonetheless, the combination of high per-unit value, procedural centrality, and recurring consumable revenue keeps biopsy systems the dominant product type across the forecast period.

By Biopsy Technique

Dominant Subsegment: Core Needle Biopsy.

The core needle biopsy segment accounted for 46% of the Breast Biopsy market in 2025. Core needle biopsy is the leading application because it has become the clinical standard of care for sampling both palpable and image-detected breast lesions, offering an optimal balance of diagnostic accuracy, minimal invasiveness, and cost relative to surgical excision. Its compatibility with ultrasound, stereotactic, and MRI guidance makes it applicable across nearly the full spectrum of lesion types and clinical settings, from hospital breast centers to outpatient imaging clinics. Vacuum-assisted biopsy is the fastest-growing application, propelled by its superior sampling volume for calcifications and complex lesions and its expanding therapeutic role in complete lesion excision. Fine needle aspiration remains in routine use for cystic and clearly benign-appearing lesions and for rapid triage, while surgical biopsy is increasingly reserved for cases where needle-based sampling is inconclusive or technically infeasible. The breadth of clinical indications and the sheer procedure volume secure core needle biopsy's leadership across the forecast period.

Breast Biopsy Market Region Analysis

Dominant Region: North America

North America accounted for 41% of the global Breast Biopsy market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature, well-reimbursed mammography screening infrastructure, high breast cancer awareness, dense-breast notification requirements that drive supplemental screening and biopsy referrals, and the concentrated presence of leading device manufacturers including Hologic, BD, and Mammotome. The United States hosts extensive hospital, imaging-center, and ambulatory surgical center capacity for image-guided breast biopsy, supported by broad private and public insurance coverage. Continuous product innovation, including newly cleared MRI-compatible vacuum-assisted systems and contrast-enhanced mammography biopsy platforms, together with rapid replacement of aging equipment, sustains high per-capita procedure volumes and device spending. Canada and Mexico contribute smaller but steadily growing volumes as screening programs expand.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Breast Biopsy market. The region's elevated CAGR is driven by rapidly rising breast cancer incidence, expanding mammography and ultrasound screening infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China is scaling hospital-based breast imaging and biopsy capacity as national cancer screening initiatives expand, India is building private-hospital and diagnostic-chain infrastructure supported by rising awareness campaigns, Japan is upgrading to digital tomosynthesis and vacuum-assisted systems, and South Korea and Australia benefit from well-established organized screening programs. Government healthcare investment, growing private insurance penetration, and rising availability of trained breast radiologists are accelerating adoption of image-guided biopsy technologies, positioning Asia-Pacific as the principal source of incremental market growth over the forecast period.

Regional Commentary

North America

North America accounted for 41% of the global Breast Biopsy market revenue in 2025. The United States dominates on the strength of its mature screening infrastructure, dense-breast notification laws, broad reimbursement coverage, and concentration of leading manufacturers, while continuous product innovation and rapid equipment replacement cycles reinforce its leadership.

Europe

Europe is a large and advanced regional market, supported by organized national breast-screening programs, established regulatory frameworks under the EU Medical Device Regulation, and growing adoption of tomosynthesis and contrast-enhanced mammography-guided biopsy. Germany, the United Kingdom, France, Italy, and Spain anchor regional demand, supported by rising geriatric populations and continued investment in digital breast imaging infrastructure.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising breast cancer incidence, rapid expansion of mammography and diagnostic imaging infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's hospital screening build-out, India's expanding private diagnostic network, and Japan's shift toward digital tomosynthesis and vacuum-assisted biopsy are accelerating regional growth.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding breast cancer awareness campaigns, gradual build-out of mammography and ultrasound screening infrastructure, and growing public-private partnerships to improve early detection are broadening access to breast biopsy services, even as capital constraints and a shortage of trained specialists continue to temper the pace of adoption.

Breast Biopsy Market Competitive Landscape

The Breast Biopsy market is classified as Moderately Concentrated. A group of integrated breast-health leaders with broad imaging, biopsy, and accessory portfolios, including Hologic, BD, and Mammotome, anchors the top tier through installed-base scale and end-to-end product ecosystems, while diversified medical device manufacturers such as Argon Medical Devices, Merit Medical Systems, GE HealthCare, Cook Medical, Stryker, Planmed Oy, and Siemens Healthineers compete through complementary needle, accessory, imaging, and guidance-system portfolios, sustaining active innovation and competitive intensity across the value chain.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with a small group of breast-health specialists leading and a broader field of diversified device manufacturers competing on components and adjacent technology.
• Leading players: Hologic, BD, and Mammotome anchor the top tier through broad installed bases of biopsy systems and integrated breast-imaging platforms.
• Geographic reach: Leading players operate global distribution and service networks spanning hospitals, imaging centers, and ambulatory sites across North America, Europe, and expanding parts of Asia-Pacific.
• Product portfolio strength: Top players offer end-to-end portfolios spanning biopsy needles, vacuum-assisted and MRI-compatible systems, guidance platforms, and tissue-marking accessories.
• Guidance-technology integration: Ownership of complementary mammography, tomosynthesis, and ultrasound imaging platforms that integrate directly with biopsy guidance is a decisive advantage for vendors such as Hologic, Siemens Healthineers, GE HealthCare, and Planmed Oy.
• Innovation focus: MRI-compatible in-room vacuum-assisted systems, contrast-enhanced mammography-guided biopsy, automated spring-loaded core devices, and AI-assisted lesion targeting are key areas of active development.
• Supply-chain resilience: Manufacturing capacity and needle-supply reliability have become a competitive differentiator following recent industry-wide stereotactic needle shortages.
• Manufacturing capabilities: Automated needle and probe manufacturing, disposable consumable production scale, and regulatory-cleared quality systems are key competitive moats.

Breast Biopsy Market Recent Developmental Activities

In March 2026, Mammotome (a Danaher company) secured FDA clearance for the Mammotome Prima(TM) MR Dual Vacuum-Assisted Breast Biopsy System, the first system designed to be positioned directly in the MRI scanner room, alongside the new HydroMARK(TM) Plus biopsy site marker for MR. Strategic significance: Expands Mammotome's MRI-guided biopsy portfolio and strengthens its position in the fast-growing MRI guidance segment.

In February 2026, Mammotome introduced the Mammotome Prima(TM) MR system in Europe, securing CE mark ahead of its U.S. clearance and expanding access across select global markets throughout 2026. Strategic significance: Establishes an early European foothold for in-room MRI vacuum-assisted biopsy technology.

Breast Biopsy Market Segmentation

Breast Biopsy Market by Product Type

• Biopsy Needles
• Biopsy Systems
• Guidance Systems
• Accessories

Breast Biopsy Market by Biopsy Technique

• Core Needle Biopsy
• Fine Needle Aspiration
• Vacuum-Assisted Biopsy
• Surgical Biopsy

Breast Biopsy Market by Guidance Technology

• Ultrasound
• Stereotactic
• MRI
• Tomosynthesis/Mammography
• Others

Breast Biopsy Market by Lesion Type

• Palpable
• Non-Palpable

Breast Biopsy Market by End-Users

• Hospitals
• Diagnostic Imaging Centers
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Breast Biopsy Market by Geography

• North America Breast Biopsy Market
• United States Breast Biopsy Market Size in USD million (2023-2034)
• Canada Breast Biopsy Market Size in USD million (2023-2034)
• Mexico Breast Biopsy Market Size in USD million (2023-2034)
• Europe Breast Biopsy Market
• Germany Breast Biopsy Market Size in USD million (2023-2034)
• United Kingdom Breast Biopsy Market Size in USD million (2023-2034)
• France Breast Biopsy Market Size in USD million (2023-2034)
• Italy Breast Biopsy Market Size in USD million (2023-2034)
• Spain Breast Biopsy Market Size in USD million (2023-2034)
• Rest of Europe Breast Biopsy Market Size in USD million (2023-2034)
• Asia-Pacific Breast Biopsy Market
• China Breast Biopsy Market Size in USD million (2023-2034)
• Japan Breast Biopsy Market Size in USD million (2023-2034)
• India Breast Biopsy Market Size in USD million (2023-2034)
• Australia Breast Biopsy Market Size in USD million (2023-2034)
• South Korea Breast Biopsy Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Breast Biopsy Market Size in USD million (2023-2034)
• Rest of the World (RoW) Breast Biopsy Market
• Middle East Breast Biopsy Market Size in USD million (2023-2034)
• Africa Breast Biopsy Market Size in USD million (2023-2034)
• South America Breast Biopsy Market Size in USD million (2023-2034)

Key Takeaways from the Breast Biopsy Market Report Study

• Market size analysis for the current Breast Biopsy market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that have happened over the last 3 years.
• Key companies dominating the global Breast Biopsy market.
• Various opportunities available for competitors in the Breast Biopsy market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Breast Biopsy market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Breast Biopsy market growth in the future?

Target audience who can benefit from this Breast Biopsy market report study

• Breast Biopsy product providers
• Research organizations and consulting companies
• Breast Biopsy -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Breast Biopsy
• Various end-users who want to know more about the Breast Biopsy market and the latest technological developments in the Breast Biopsy market.

Frequently Asked Questions:

Q1. What is the growth rate of the Breast Biopsy market?

The Breast Biopsy market is projected to expand at a CAGR of 5.8% during the forecast period from 2026 to 2034.

Q2. What is the market size of the Breast Biopsy market?

The Breast Biopsy market is estimated at USD 2.47 billion in 2025 and is projected to reach USD 4.12 billion by 2034.

Q3. Which region dominates the Breast Biopsy market?

North America dominated the Breast Biopsy market with a 41% share of global revenue in 2025, supported by a mature mammography screening infrastructure, dense-breast notification requirements, broad reimbursement coverage, and the concentrated presence of leading device manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Breast Biopsy market?

The principal drivers are the rising global incidence of breast cancer; the expansion of mammography, tomosynthesis, and supplemental screening programs that increase detection of non-palpable lesions; the structural shift from surgical to minimally invasive needle-based biopsy; continuous product innovation in MRI-compatible and contrast-enhanced guidance platforms; and the expansion of outpatient and ambulatory breast-biopsy capacity.

Q5. Who are the major players in the Breast Biopsy market?

The major players include Hologic, Inc., BD (Becton, Dickinson and Company), Mammotome, Argon Medical Devices, Merit Medical Systems, Inc., GE HealthCare, Cook Medical, Stryker, Planmed Oy, and Siemens Healthineers, among other active providers profiled in the Competitive Landscape section. Hologic, BD, and Mammotome lead through broad installed bases and integrated breast-imaging and biopsy portfolios.